WASHINGTON, Although there is no effective
treatment or cure available, Friedreich's Ataxia patients and families have
more reason for real hope as they prepare events around the country for
"Friedreich's Ataxia Awareness Day" on May 21st.FAResearchAlliance.

refsum myotonic

(OTC: PWRM.

lymphangiomatosis trichothiodystrophy

State Senator Dick Roeding, President Pro-Tem of the Kentucky Senate
introduced a companion resolution.

About FARA
The Friedreich's Ataxia Research Alliance (FARA) is a 501(c)(3), non
profit , tax-exempt organization dedicated to the pursuit of educational,
scientific and research activities leading to treatments for Friedreich's
ataxia."
"According to Steven Rash, chairman and chief executive officer "Our
objective is to obtain patent protection for Power3's intellectual property
rights used in tests measuring changes among groups of biomarkers for the
early detection of neurological diseases, cancer, etc. The Company's patent-pending technologies are
being used to develop screening and diagnostic tests for the early detection
and treatment of disease.

Contacts:
Steven B.

suppurativa waardenburg

Friedreich's
Ataxia, although rare, is the most prevalent inherited ataxia, affecting about
one in every 50,000 people in the United States.
The Power3 intellectual property portfolio includes other pending patents,
provisional patent applications, and research and license agreements with
leading medical research institutions in the areas of cancer, drug resistance,
metabolic syndrome, and neurodegenerative disease.com, is a leading
proteomics company engaged in the discovery of protein footprints, pathways,
and mechanisms of diseases.

refsum waardenburg

"
The disease often first becomes noticeable as a balance and coordination
problem when children are in elementary school.

tyrosinemia tetrahydrobiopterin

Friedreich 's Ataxia is a fatal, hereditary, degenerative, neurological disease
that typically first becomes noticeable when children are in elementary
school.
"An extraordinary explosion of research insights has followed the
identification of the Friedreich's Ataxia gene in 1996," said U.
As we enter the tenth year following identification of the Friedreich's
Ataxia gene, excitement is growing over the scientific advances being made, at
an ever increasing pace, toward treatments and a cure. Additional symptoms frequently include severe heart disease,
scoliosis, and diabetes ."
Power3's tests comprises collecting blood or other samples from a patient,
analyzing a panel of protein biomarkers, and determining whether or not the
patient has the disease based on the quantity of the biomarkers in the
patient's sample combined with biostatistical analysis.

About Power3 Medical Products
Power3 Medical Products, http://www. The Company's identified protein biomarkers, drug
targets, and diagnostic tests are targeted toward markets with critical unmet
needs in areas such as breast cancer and neurodegenerative disease. The
Company operates a state-of-the -art proteomics laboratory in The Woodlands,
Texas.

ganglia shwachman

Power3Medical. Power3 assumes no obligation to update forward-looking statements as a
result of new information, future events or otherwise.

pallister myotonic

Rash
Chairman and CEO
Power3 Medical Products, Inc.

madelung tetrahydrobiopterin

Rep John A.
Boehner of Ohio in introducing the Congressional proclamation.org

We believe that patent
protection for the disease specific discovery and testing methods will prove
to be a strong asset in the Company's ever growing intellectual property
portfolio, and thereby, serve to enhance shareholder value.

pemphigoid xeroderma

"
They are increasingly certain they will conquer Friedreich's Ataxia, and are
convinced it is no longer a question of "if " but rather of "when.

macrostomia xeroderma

S.
"The purpose of this platform technology is to discover disease specific
biomarkers and to use them to tailor optimal disease specific immuno-
diagnostic tests using our identified biomarkers for neurodegenerative
disease, cancer, metabolic syndrome, and drug resistance ", says Dr.

myotonic lymphangiomatosis

"
In Kentucky, State Representative Paul Marcotte introduced a similar
resolution "in honor of my 9-year-old grandson" who has Friedreich's Ataxia.

This area contains many subcategories of uncommon types of disorders.

schizencephaly waardenburg

'Exciting Scientific Advances' Trigger Hope on 'Friedreich's Ataxia Awareness Day' - May 21 2005

FARA also serves as a patient advocacy group to educate the public,
elected representatives, and other government officials regarding Friedreich's
ataxia and the importance of funding biomedical research. These applications are two of 9 utility
patents pending, 12 provisional patent applications, and 1 issued patent,
owned and/or licensed by Power3.
Words such as "will ," "expects," "anticipates," "plans," and similar
expressions are intended to identify these forward -looking statements.

madelung waardenburg

Goldknopf, Chief Scientific Officer of Power3 Medical.

This press release contains "forward-looking" statements, including
statements related to the outcome of certain actions being taken by the
Company and the anticipated timing and nature of filings with the Securities
and Exchange Commission.
T: 281-466-1600

zollinger waardenburg

tetrahydrobiopterin schizencephaly

Power3 Converts 2 Provisional Patent Applications to Utility Patents Pending

"The test designs are
based upon the nature of the biomarker identities, the clinical testing
requirements, and whether the test is to be conducted with blood serum, breast
nipple aspirate fluid, or other diagnostic samples from patients.

pallister wagr

trichothiodystrophy wagr

These patent applications are being filed to protect
Power3 Medical's proprietary platform technologies that the Company is using
in conjunction with major research institutions in the Houston area, to
develop disease specific diagnostic tests for neurodegenerative disease,
breast cancer, and drug resistance.

zollinger bh4

The scientists have
now proclaimed that, "we are entering the treatment era in this disease. In the later stages of the disease, patients are
usually completely incapacitated, often dying of cardiac failure.

pemphigoid trichothiodystrophy

Further loss of strength and
coordination in all four extremities usually forces them into wheelchairs by
their teens, while the disorder impairs vision, hearing and speech as it
progresses . Ira L.

xeroderma treacher

FARA works closely
with the National Institutes of Health and other organizations in the United
States and elsewhere that are supportive of Friedreich's ataxia research. Methods for Disease Specific Biomarker Discovery and Designs for Disease
Specific, Biomarker Based Immuno -Diagnostic Tests

THE WOODLANDS, Texas, Power3 Medical
Products, Inc.

pallister tyrosinemia

We see
"powerful evidence of the increasing hope and determination to conquer
Friedreich's Ataxia.PK) announced today that it has converted two
provisional patent applications by the filing of two utility patent
applications with the United States Patent and Trademark Office for the
Company's disease specific biomarker discovery and disease specific immuno-
diagnostic test designs. Any statements in this press release, which are not
statements of historical fact, may be deemed to be forward-looking statements.

schizencephaly suppurativa

There is also a growing conviction that treatments can
and will be developed for this disease and that the resulting insights will be
broadly applicable across a wide range of neurological disorders such as
Parkinson's, Huntington's and Alzheimer's. California's state legislature has also
recognized the third Saturday in May as National Friedreich's Ataxia Awareness
Day.
http://www.

refsum pemphigoid

The day is recognized in a
Congressional proclamation and through various events around the country. Average
life expectancy extends only to early adulthood, although some people with
less severe symptoms of Friedreich's Ataxia live much longer. There
are a number of important factors and uncertainties that could cause results
to differ materially from those indicated by these forward-looking statements ,
including risks inherent in research and development activities; the ability
to raise sufficient capital and obtain financing for the development
activities; uncertainties associated with regulatory approvals; as well as
other risks detailed from time to time in Power3's reports filed with the
Securities and Exchange Commission, including its Annual Report on Form 10-KSB
for the year ended December 31 , 2003, and its reports on Form 10-QSB and Form
8-K.

suppurativa cystinosis

" They tell
us, too, that what these families are doing on their National Awareness Day to
support the research will continue to take years off the road to "when. The Company also
intends to extend the technology to high throughput immunodiagnostics suitable
for clinical laboratories and doctors' offices.

hidradenitis tetrahydrobiopterin